Cancel

Pediatric RSV Prophylaxis: An Evolving Landscape for Prevention " A Wheel of Knowledge Challenge!

Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia in children younger than 1 year of age in the United States. Although certain infants and young children are at higher risk for severe illness due to premature birth or comorbid conditions, the majority of pediatric RSV hospitalizations occur in healthy infants. Emerging passive immunization options, which include nirsevimab and a maternal RSV vaccine, provide important new tools that offer RSV protection...
This continuing education activity is provided by Vindico Medical Education.

Beyond Avoidance: IgE-Mediated Food Allergies " Therapeutic Innovations to the Rescue

In the United States, food-induced allergic reactions are the leading cause of anaphylaxis in hospital emergency departments. Among these, immunoglobulin E (IgE)-mediated food allergies are the most common, and they pose significant risks, including cardiac arrest and respiratory failure. Traditionally, treatment options for IgE-mediated food allergies have been primarily limited to food avoidance and anaphylaxis prevention. However, recent years have brought the FDA approval of the first oral...
Vindico Medical Education

What’s New With HER2: Charting New Paths in NSCLC Care - Module 2: Current and Emerging Treatments for HER2-Mutated NSCLC

STATEMENT OF NEED In recent years, the discovery of oncogenic drivers and development of targeted therapies have transformed the treatment of advanced non"small cell lung cancer (NSCLC). Alterations in human epidermal growth factor receptor 2 (HER2), which include gene mutations, gene amplifications, and protein overexpression, are therapeutic targets. Several HER2-targeted therapies are under investigation in NSCLC and have demonstrated clinical benefit, with trastuzumab deruxtecan re...
i3 Health

Podcast: What’s New With HER2: Charting New Paths in NSCLC Care - Module 2: Current and Emerging Treatments for HER2-Mutated NSCLC

STATEMENT OF NEED In recent years, the discovery of oncogenic drivers and development of targeted therapies have transformed the treatment of advanced non"small cell lung cancer (NSCLC). Alterations in human epidermal growth factor receptor 2 (HER2), which include gene mutations, gene amplifications, and protein overexpression, are therapeutic targets. Several HER2-targeted therapies are under investigation in NSCLC and have demonstrated clinical benefit, with trastuzumab deruxtecan re...
i3 Health

Therapy Tidbits Summer 2021

Therapy Tidbits – Summer 2021 is a 1-hour online continuing education (CE) course comprised of select articles from the Summer 2021 issue of The National Psychologist, a private, independent, quarterly newspaper intended to keep psychologists informed about practice issues. The articles included in this course are: • Improving Health through Community Policies Gains Momentum – Provides an overview of the Blue Zone Project and the impact on community members’ health. • Psychologis...
Professional Development Resources

Therapy Tidbits Spring 2022

Therapy Tidbits – Spring 2022 is a 1-hour online continuing education (CE) course comprised of select articles from the Summer 2022 issue of The National Psychologist, a private, independent, quarterly newspaper intended to keep psychologists informed about practice issues. The articles included in this course are: No Surprises Act (NSA) Clarifies Patient Rights – Discusses the NSA and provides guidance in demonstrating good faith attempts at compliance. Pharmacists Can be Valuable A...
Professional Development Resources

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map